论文部分内容阅读
晚期肺癌疗效甚差，其综合治疗仍是目前临床研究的重点，对２３例失去手术机会的晚期肺癌进行支气管动脉灌注化疗（ＢＡＩ）和肿瘤体内局部免疫肿瘤即双介入治疗（Ａ组），并与同期肺癌１２例单纯瘤体内局部免疫治疗（Ｂ组）、１６例单纯ＢＡＩ化疗（Ｃ组）、１８例传统化疗（Ｄ组）比较疗效，Ａ组完全缓解（ＣＲ）２例，部分缓解（ＰＲ）１８例，近期有效率ＣＲ＋ＰＲ８６．９６％，明显优于Ｂ组ＣＲ＋ＰＲ５０．００％，Ｃ组ＣＲ＋ＰＲ５６．２５％和Ｄ组ＣＲ＋ＰＲ３３．３３％，差异有统计学意义（χ２＝１２．８２１，Ｐ＜０．０１）。Ａ组７例重获Ⅱ期手术适应症，２例手术切除术后病理显示癌细胞大片变性、坏死。单纯局部免疫治疗方法简单，近期疗效接近Ｃ、Ｄ两组，毒副作用少，双介入治疗晚期肺癌具有较大的应用价值，为晚期肺癌提供了新的有效、简便的治疗方法。
The efficacy of advanced lung cancer is very poor, and its comprehensive treatment is still the focus of current clinical research. 23 cases of advanced lung cancer with no chance of surgery are undergoing bronchial arterial infusion chemotherapy (BAI) and local tumor immunotherapy, ie double interventional therapy (group A), and Compared with 12 patients with lung cancer during the same period, local immunotherapy alone (group B), 16 patients with pure BAI chemotherapy (group C), and 18 patients with traditional chemotherapy (group D) were compared. In group A, 2 patients had complete remission (CR) and partial remission ( PR) 18 cases, the recent effective rate of CR + PR 86.96%, significantly better than CR + PR 50.00% in group B, CR + PR 56.25% in group C and CR + PR 33.33% in group D, the difference was statistically significant (χ2 = 12.8211, P <0.01). In group A, 7 patients received indications for stage II surgery, and 2 cases showed pathological degeneration and necrosis of cancer cells after surgical resection. The simple local immunotherapy method is simple, the short-term efficacy is close to the C and D groups, and the toxic and side effects are few. The double-interventional treatment of advanced lung cancer has great application value, and provides a new effective and simple treatment method for advanced lung cancer.